Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > What have we got here?

<< Previous

Bullboard Posts

Next >>

Comment by JohnnyYegon Jun 20, 2023 1:52pm

140 Views

Post# 35505675

RE:RE:What have we got here?

And exactly how many "sellers" of the 64,092,904 outstanding shares are selling? And conversely, how many are holding pat? Might give you some idea about the sentiment held by shareholders towards the company and future of Pelareorep.

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities